Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript provided. The company highlights a net cash position of US$ 42 million as of December 31, 2024, improving from a net debt position of US$ 84 million, indicating improved financial stability. The average finance cost is stated to be Rs. 5.5%, but no comments on raising additional debt. Management mentions expecting tariff announcements by July 2025 and will provide better clarity in the next earnings call. Investments in Pen-G, Biosimilar, and CDMO businesses are ongoing but funded th

Any current/future capex/capital investment/strategic investment?

Invested around Rs. 2,700 crores in Penicillin-G (Pen-G) plant, with potential EBITDA > Rs. 1,000 crores depending on prices. Biosimilar business investment at around US$ 400 million; expected inflection and growth stabilization from 2028 to 2030 with 7 products in regulated markets. CDMO business (TheraNym) investment close to Rs. 1,000 crores for 15 KL bioreactor capacities; plant commissioning expected in Q2 FY27, with revenues from FY28. Expansion of formulation manufacturing capacity to 60 billion units plus, with further capacity enhancements planned to support growth. Commercial

Future growth expectations in sales/revenue/volumes?

FY26 growth expected at high single digit excluding transient product (Q20, Q15, Q7). Europe forecasted to grow around 8-9%, driven by new product launches including 6 LOE (Loss of Exclusivity) products (Q19, Q14, Q9). US business growth seen as muted in FY26; focus remains on volume gains and new launches in oral solids and injectables (Q19, Q13, Q10). Pen-G plant production included for 6-8 months, tentative contribution of ~3-6% of revenues (Q19). Biosimilar business expected to inflect around FY28 with 7 products in regulated markets by 2030 (Q18, Q16). China OSD plant commercial

Future growth expectations in earnings/operating earnings/profits/EPS?

Aurobindo Pharma targets high single-digit revenue growth for FY26, excluding transient products. EBITDA margins are expected to be maintained at current levels in FY26. Europe business growth to sustain with planned launches including loss of exclusivity (LOE) products driving stronger growth. Biosimilar business is expected to show an inflection from FY28 onwards with stabilization by 2030. The Pen-G plant is projected to contribute positively once fully operational, with potential EBITDA of over Rs. 1,000 crore. CDMO business commercial revenues anticipated from FY28, with capacity enhancem

Aurobindo Pharma LtdQ1 FY26Pharmaceuticals & Biotechnology

Aurobindo Pharma Ltd Q1 FY26 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,658P/E: 24.8Market Cap: ₹93.7K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 4

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 4

→FY26 growth expected at high single digit excluding transient product (Q20, Q15, Q7).
→Europe forecasted to grow around 8-9%, driven by new product launches including 6 LOE (Loss of Exclusivity) products (Q19, Q14, Q9).
→US business growth seen as muted in FY26; focus remains on volume gains and new launches in oral solids and injectables (Q19, Q13, Q10).
→Pen-G plant production included for 6-8 months, tentative contribution of ~3-6% of revenues (Q19).
→Biosimilar business expected to inflect around FY28 with 7 products in regulated markets by 2030 (Q18, Q16).
→China OSD plant commercialized, expected to contribute revenues in FY26 with further capacity expansion planned (Q6).
→US-based OSD and topical/transdermal/respiratory plants expected commercial from FY26 onwards (Q6).
→Growth markets like Indonesia, China, Canada targeted for expansion (Q6).

Margin guidance

Category 3

→Aurobindo Pharma targets high single-digit revenue growth for FY26, excluding transient products.
→EBITDA margins are expected to be maintained at current levels in FY26.
→Europe business growth to sustain with planned launches including loss of exclusivity (LOE) products driving stronger growth.
→Biosimilar business is expected to show an inflection from FY28 onwards with stabilization by 2030.
→The Pen-G plant is projected to contribute positively once fully operational, with potential EBITDA of over Rs. 1,000 crore.
→CDMO business commercial revenues anticipated from FY28, with capacity enhancements underway.
→US business growth expected to be moderate; injectable and oral solids segments are key near-term drivers.
→Other operating income likely to stabilize around Rs. 200 crore plus.
→Margins expected to benefit from normalization in new units (e.g., China plant) and easing raw material costs.
→Tariff-related risks remain uncertain, with clarity anticipated post-announcement in July 2025.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the transcript provided.
→The company highlights a net cash position of US$ 42 million as of December 31, 2024, improving from a net debt position of US$ 84 million, indicating improved financial stability.
→The average finance cost is stated to be Rs. 5.5%, but no comments on raising additional debt.
→Management mentions expecting tariff announcements by July 2025 and will provide better clarity in the next earnings call.
→Investments in Pen-G, Biosimilar, and CDMO businesses are ongoing but funded through prior investments (Rs. 2,700 crores in Pen-G; approx. Rs. 1,000 crores in CDMO).
→No indication of equity fundraising mentioned during the call.

Order book

The transcript does not explicitly mention details about the current or expected order book or pending orders for Aurobindo Pharma Limited. However, some relevant points related to business outlook and order execution are: - Multiple product launches planned in FY26, including several oncology oral solids and LOE (Loss of Exclusivity) products. - Biosimilar business expected to contribute significantly by 2030-31 with revenues ranging US$ 250-400 million. - Expansion of manufacturing capacities in China, US (Dayton and Raleigh plants), and Europe supports future order fulfillment. - Production resumption pending at Pen-G plant after fire accident; regulatory approvals awaited. - Continuous growth momentum in Europe and growth markets, with new launches and enhanced supply chain efficiency. - Expectation of high single-digit revenue growth excluding transient product in FY26. No concrete figures for order book or pending orders were provided.

Capex plans

Yes

→Invested around Rs. 2,700 crores in Penicillin-G (Pen-G) plant, with potential EBITDA > Rs. 1,000 crores depending on prices.
→Biosimilar business investment at around US$ 400 million; expected inflection and growth stabilization from 2028 to 2030 with 7 products in regulated markets.
→CDMO business (TheraNym) investment close to Rs. 1,000 crores for 15 KL bioreactor capacities; plant commissioning expected in Q2 FY27, with revenues from FY28.
→Expansion of formulation manufacturing capacity to 60 billion units plus, with further capacity enhancements planned to support growth.
→Commercialized China OSD plant with 2 billion units capacity during FY25; further expansions planned medium term, expected to contribute revenues in FY26.
→US-based OSD plant at Dayton to be commercialized during FY26; Raleigh plant to include transdermal and respiratory products soon.
→Focus continues on respiratory product development partnerships to support complex product launches.

How does Aurobindo Pharma Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aurobindo Pharma Ltd

Rev 4Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aurobindo Pharma Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio